Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers by Rodriguez-Barrueco, Ruth et al.
Inhibition of the autocrine IL-6–JAK2–
STAT3–calprotectin axis as targeted
therapy for HR−/HER2+ breast cancers
Ruth Rodriguez-Barrueco,1,8 Jiyang Yu,2,3,8 Laura P. Saucedo-Cuevas,1 Mireia Olivan,1
David Llobet-Navas,1 Preeti Putcha,4 Veronica Castro,4 Eva M. Murga-Penas,4 Ana Collazo-Lorduy,1
Mireia Castillo-Martin,1 Mariano Alvarez,2,3 Carlos Cordon-Cardo,1 Kevin Kalinsky,5
Matthew Maurer,4,5 Andrea Califano,2,3,6,7 and Jose M. Silva1
1Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA; 2Department of Systems
Biology, Center for Computational Biology and Bioinformatics, 3Herbert Irving Comprehensive Cancer Center, Columbia
University, New York, New York 10032, USA; 4Institute for Cancer Genetics, Department of Pathology, Irving Cancer Research
Center, ColumbiaUniversity, NewYork,NewYork 10032, USA; 5Department ofMedicine, ColumbiaUniversityMedical Center,
New York, New York 10032, USA; 6Department of Biomedical Informatics, 7Department of Biochemistry and Molecular
Biophysics, Institute for Cancer Genetics, Columbia University, New York, New York 10032
HER2-positive (HER2+) breast adenocarcinomas are a heterogeneous group in which hormone receptor (HR) status
influences therapeutic decisions and patient outcome. By combining genome-wide RNAi screens with regulatory
network analysis, we identified STAT3 as a critically activated master regulator of HR−/HER2+ tumors, eliciting
tumor dependency in these cells. Mechanistically, HR−/HER2+ cells secrete high levels of the interleukin-6 (IL-6)
cytokine, inducing the activation of STAT3, which in turn promotes a second autocrine stimulus to increase
S100A8/9 complex (calprotectin) production and secretion. Increased calprotectin levels activate signaling pathways
involved in proliferation and resistance. Importantly, we demonstrated that inhibition of the IL-6–Janus kinase 2
(JAK2)–STAT3–calprotectin axis with FDA-approved drugs, alone and in combination with HER2 inhibitors,
reduced the tumorigenicity of HR−/HER2+ breast cancers, opening novel targeted therapeutic opportunities.
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HER2/ERBB2 is a receptor tyrosine kinase found overex-
pressed in 15%–20% of breast tumors (HER2+ tumors)
(Hynes and Lane 2005). It belongs to a family of four recep-
tors (EGFR/HER1, HER2, HER3, and HER4) involved in
cell signaling networks regulating cell growth, survival,
and differentiation (Hynes and Lane 2005; Lemmon and
Schlessinger 2010). In general, EGFR/HER receptors are
activated through dimerization, which is promoted by
the binding of cognate growth factors. However, HER2 is
a unique member of the family and does not rely on direct
ligand binding for activation; instead, it is activated
through heterodimerization with other EGFR/HER fami-
ly members that are ligand-bound (Citri and Yarden
2006). When aberrantly overexpressed, HER2 is able to
homodimerize and initiate proliferation and prosurvival
signal transduction in a ligand-independent fashion (Citri
and Yarden 2006).
Despite the existence of several HER2-specific targeted
therapies that have drastically improved the treatment of
HER2+ patients (trastuzumab, lapatinib, TDM1, and per-
tuzumab), tumor progression remains transient (Hynes
and Lane 2005; Tagliabue et al. 2010). Thus, there is a
need to find complementary, therapeutic targets that
hold the potential for more effective treatments.
Although, HER2+ tumors are commonly considered as
a single entity, there is increasing evidence indicating
that important intrinsic differences associated with hor-
mone receptor (HR) status exist. Each of the two groups,
HR+ and HR−, represents about half of all HER2+ breast
cancers.
Compared with HR+/HER2+, HR−/HER2+ tumors
present worse histopathological characteristics (larger
size, lymph node involvement, higher American Joint
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Committee on Cancer [AJCC] stage, and higher histologi-
cal grade) (Vaz-Luis et al. 2012).HR+/HER2+ tumors prefer-
entially recur in bones, while there is a strong trend for
more visceral metastases in the HR−/HER2+ cancers (Pal-
uch-Shimon et al. 2009; Vaz-Luis et al. 2012). Moreover,
despite a higher rate of pathologic complete responses
(pCRs) to neoadjuvant chemotherapy (Hurley et al. 2006;
Vaz-Luis et al. 2012), HR−/HER2+ patients still have an in-
creased risk of death within 5 years of diagnosis (Vaz-Luis
et al. 2012). Intrinsic differences betweenHR−/HER2+ and
HR+/HER2+ breast cancers are also found at themolecular
level, as highlighted by unsupervised cluster analysis of
gene expression profiles. The latter clearly identifies two
distinctHER2+ subtypes.Most tumors clinically classified
as HR+/HER2+ fall in the luminal B subtype, while most
HR−/HER2+ tumors are part of the HER2-enriched sub-
type (Perou et al. 2000; Sotiriou and Pusztai 2009).
Indeed, while HR+/HER2+ patients benefit from anti-
hormonal and HER2 targeted therapies (Kaufman et al.
2009), the outcome for HR−/HER2+ patients strongly de-
pends on their response to chemotherapy as well as anti-
HER2 therapy. Thus, to identify genes that represent nov-
el mechanistic dependencies in HR−/HER2+ breast cancer
cells, we designed an integrative approach that combines
functional genomic (RNAi screens) (Luo et al. 2008; Silva
et al. 2008) and computational (Basso et al. 2005;Margolin
et al. 2006; Carro et al. 2010; Lefebvre et al. 2010; Piovan
et al. 2013) algorithms.
Our integrative analysis identified STAT3 as a de novo
master regulator (MR) gene associated with HER2-medi-
ated transformation in HR− breast cancer cells. Impor-
tantly, we demonstrate that aberrant STAT3 activity is
necessary to maintain the HR−/HER2+ tumor state, thus
representing a nononcogene dependency in these tumors.
Mechanistically, we found that HR−/HER2+ breast tu-
mors secrete high levels of interleukin-6 (IL-6). This auto-
crine mechanism induces the activation of STAT3 via the
canonical Janus kinase 2 (JAK2)/STAT3 pathway. Aber-
rant STAT3 activity induces up-regulation and secretion
of the S100A8/9 complex (calprotectin), thus triggering a
second autocrine stimulus that enhances proliferation
and survival. As a result, disruption of the “IL-6–JAK2–
STAT3–S100A8/9 cascade” compromises HR−/HER2+
cell viability, suggesting that the components of this path-
way represent putative therapeutic targets in HR−/HER2
tumors. Importantly, small molecule inhibitors and
blocking antibodies for components of this double auto-
crine loop are already FDA-approved or in clinical trials.
Here, we demonstrate that blocking the IL-6 receptor
(IL-6R) with the humanized monoclonal antibody tocili-
zumab (Patel and Moreland 2010; Navarro-Millan et al.
2012), STAT3 inactivation with the dual JAK1/2 inhibitor
ruxolitinib (Mascarenhas and Hoffman 2012; Mesa et al.
2012), or calprotectin inhibition with the small molecule
inhibitor tasquinimod (Dalrymple et al. 2007, 2012), alone
or in combination with anti-HER2 therapies, compromis-
es the viability of HR−/HER2+ breast cancer cells. The
availability of FDA-approved inhibitors to target this nov-
elmechanism represents an exciting opportunity for rapid
translation of these findings to the clinics.
Results
Genome-wide RNAi screens and MR analysis
identify STAT3 as an essential MR gene in
HR−/HER2+ cells
To identify critical regulators of HR−/HER2+ breast
cancer cell homeostasis, we developed an integrative ap-
proach that combines pooled, genome-wide loss-of-func-
tion studies and systems biology methods for the reverse
engineering and interrogation of regulatory networks
(Fig. 1A).
RNAi is a powerful genetic strategy to interrogate gene
function by loss-of-function studies. We (Silva et al. 2008;
Rodriguez-Barrueco et al. 2013; Yu et al. 2013) and others
(Luo et al. 2008; Schlabach et al. 2008) have developed
RNAi-based genetic approaches to perform high-through-
put (HTP) screens in mammalian systems. Using this
technology, we performed genome-wide pooled RNAi
screens to find gene functions that are required to main-
tain the homeostasis of HR− mammary epithelial cells
transformed by the oncogene HER2. However, RNAi-
based screens suffer from high inherent noise and het-
erogeneity that can compromise the effective validation
of identified hits (Schultz et al. 2011). To reduce the can-
didate gene list size while increasing its robustness, we
decided to combine our genetic screens with computa-
tional approaches that are highly effective in identifying
MR genes of HR−/HER2+ tumors. These represent tran-
scription factors (TFs) and signaling proteins (SPs) that
are mechanistic regulators of the genes that are differen-
tially expressed between normal and transformed cells
from a repertoire of 780 expressed TFs and 2453 expressed
SPs that are expressed in HR−/HER2+ tumors. This is
accomplished by using MARINa (Master Regulator In-
ference Algorithm) (Carro et al. 2010; Lefebvre et al.
2010; Piovan et al. 2013) to interrogate regulatory net-
works (hereafter referred to as interactomes) inferred by
ARACNe (Algorithm for the Reconstruction of Accurate
Cellular Networks) (Basso et al. 2005; Margolin et al.
2006) from a large, tumor-specific gene expression profile
data set. Importantly, we showed that 20%–30% of the
MARINa-inferred MRs are essential for viability of the
cells that they regulate (Carro et al. 2010; Piovan et al.
2013), thus representing valuable tumor-specific targets.
We speculated that inhibiting MRs that are computation-
ally identified and also selected by the loss-of-function
screen would impact HER2-mediated transformation of
HR− mammary epithelial cells.
As the experimental model for the RNAi screens, we
chose mammary epithelial MCF-10A cells and an isogen-
ic variant transformed with an oncogenic form of HER2
(Wang et al. 2006), termed here MCF-10A/ErbB2∗. This
model system possesses several characteristics that
make it useful for our purposes. MCF-10A is a spontane-
ously immortalized, but nontransformed, human mam-
mary epithelial cell line (Soule et al. 1990; Debnath
et al. 2003). These cells exhibit numerous features of
normal breast epithelium, including diploid chromosome
genotype, lack of tumorigenicity in nude mice, lack of an-
chorage-independent growth, and dependence on growth
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Figure 1. Integrative functional studies identify STAT3 as a MR in HR−/HER2+ breast cancer cells. (A) Schematic representation of the
strategy followed to identify potential therapeutic targets in HR−/HER2+ breast tumors as described in the text. The left side shows a sim-
plified representation of the shRNA screening strategy. The right side summarizes MR analysis based on expression profiles from MCF-
10A and MCF-10A/ErbB2∗ models as well as from primary samples (TCGA [The Cancer Genome Atlas Network] and METABRIC [Mo-
lecular Taxonomyof Breast Cancer InternationalConsortium]) (for a detailed description, see theMaterials andMethods). The integration
of both approaches identified STAT3 as a putative target for HR−/HER2+ breast cancer cells. (B) Enrichment pathway analysis of the genes
that have a stronger inhibitory effect on the growth of MCF-10A/ErbB2∗ cells when compared with MCF-10A. (C ) Correlation of STAT3
activity (MR score) with the breast cancer subtype defined by HER2 and HR status in primary samples from theMETABRIC data set. The
number shown on the bars corresponds to the P-value for each correlation, and the dashed line indicates the significance threshold.
Targeted therapy for HR−/HER2+ breast cancers
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factors for proliferation and survival. In contrast, MCF-
10A/ErbB2∗ cells are transformed and form tumors when
xenografted into immunocompromised mice. Important-
ly, parental MCF-10A cells are HR−, and, when grown
on basement membrane components (BCMs), these cells
activate a morphogenetic program that induces the devel-
opment of organotypic spheroid structures. Remarkably,
this three-dimensional (3D) model bears a much closer
resemblance to the in vivo epithelial context than classi-
cal two-dimensional (2D) cultures (Debnath et al. 2002,
2003).
Using this cell model, we completed three complemen-
tary RNAi screens (Fig. 1A). In the first screen, wild-type
MCF-10A andMCF-10A/ErbB2∗ cells were grown on stan-
dard tissue culture plates. In the second screen, these cells
were grown in the presence of BCM (extracellular matrix
[ECM]-Matrigel) to form organotypic structures. Finally,
we performed an in vivo screen by transplanting MCF-
10A/ErbB2∗ cells into the mammary fat pads of immuno-
compromised (SCID) mice. We reasoned that knockdown
of genes that specifically compromised the viability of
HER2 transformed cells in all screens may represent
strong tumor dependencies that are conserved indepen-
dently of the conditions and platform. Metaanalysis iden-
tified 355 genes fulfilling this criterion. Thirty-six of them
were TFs and/or signalingmolecules (Supplemental Table
S1). Pathway analysis showed that, as expected, silencing
components of HER2 as well as canonical MAPK signal-
ing have a stronger impact on the growth of MCF-10A/
ErbB2∗ cells when compared with nontransformed MCF-
10A (Fig. 1B; Supplemental Fig. S1A,B).
We then used MARINa to computationally identify
candidate MRs of HER2-mediated transformation of
MCF-10A/ErbB2∗ breast cancer cells (Fig. 1A). First, we
analyzed 359 gene expression profiles from TCGA (The
Cancer Genome Atlas Network) primary breast cancer
samples (The Cancer Genome Atlas Network 2012) to
construct breast cancer-specific regulatory (11,415 nodes
and 112,490 edges) and signaling (11,477 nodes and
180,220 edges) networks using ARACNe, an information
theory-based reverse-engineering approach (Basso et al.
2005; Margolin et al. 2006). For SPs, we used ARACNe
to identify theirmaximum information transfer (MIT) tar-
gets, as previously done for the identification of AKT1 as
the MR of glucocorticoid resistance in T acute lympho-
blastic leukemia (T-ALL) (Piovan et al. 2013). We then in-
terrogated these interactomes with genes differentially
expressed in the MCF-10A versus MCF-10A/ErbB2∗ cells
(in both 2D and 3D cultures) (see Supplemental Table
S2) using MARINa to identify the transcriptional (Carro
et al. 2010; Lefebvre et al. 2010; Aytes et al. 2014) and sig-
naling (Piovan et al. 2013) MRs that are mechanistic regu-
lators of HER2-dependent tumorigenesis in HR− cells.
These analyses showed significant overlap ofMARINa-in-
ferred MRs between the 2D and 3D experimental models
(Fig. 1A). In fact, there was a dramatic increase compared
with the poor overlap of signature genes, by conventional
differential expression analysis (Supplemental Fig. S1C).
This suggests that, while the programs that affect HER2-
mediated transformation in these two contexts are sub-
stantially different, their transcriptional and signaling reg-
ulators are highly conserved.
Integration of 120 MRs predicted by systems biology
analysis and 36 depleted candidates from metaanalysis
of RNAi screens identified STAT3, AGRN, and GLRX
as potential MRs of MCF-10A/ErbB2∗ tumorigenesis and
thus as candidate therapeutic targets (Supplemental Fig.
S1D). We further validated STAT3 andAGRN as essential
genes in MCF-10A/ErbB2∗ cells using additional shRNAs
that efficiently silence these genes but were not included
in the initial pool library (Supplemental Fig. S1E). Individ-
ual gene validation was performed through competition
assays. These assays are based on the ability of the shRNA
vectors to coexpress the shRNA of interest and a fluores-
cent protein. Cells expressing shRNAs were mixed in a
50/50 ratio with parental cells, which did not express
the hairpin; expression of the fluorescent reporter allowed
us to track the ratio of shRNA/non-shRNA cells by flow
cytometry (Supplemental Fig. S1E). Interestingly, STAT3
and AGRN showed no differential expression in either
2D or 3D, and conventional differential expression analy-
sis could not identify them; however, MARINa analysis
successfully inferred them as differentially activated (Sup-
plemental Fig. S1D). This is a recurrent theme, as virtually
all validatedMRs in other tumor contexts were not differ-
entially expressed (Carro et al. 2010; Piovan et al. 2013).
Next, we evaluated the MR activity of STAT3 and
AGRN in primary breast cancer samples. To avoid overfit-
ting, we used a METABRIC (Molecular Taxonomy of
Breast Cancer International Consortium) data set (Curtis
et al. 2012) independent of the TCGA data from which
the networks were derived. When we compared all major
clinical subtypes based on HR and HER2 status, STAT3
was the only one of the three MRs that consistently
emerged as a HR−/HER2+-specific MR (Fig. 1C; Supple-
mental Fig. S1F).
STAT3 silencing compromised HR−/HER2+ breast cancer
cell viability in vitro and in vivo
An increasing amount of evidence suggests a pivotal role
for STAT3 as a regulator of cancer cell homeostasis (Dar-
nell 2005; Weerasinghe et al. 2007). This includes breast
cancers, where high levels of phosphorylated STAT3 (p-
STAT3) are found in ∼50% of cases and are associated
with high expression levels of growth factor receptors
EGFR and HER2 (Berclaz et al. 2001; Berishaj et al. 2007;
Hartman et al. 2011). The canonical JAK/STAT pathway
consists of a series of membrane receptors that bind to a
family of cytoplasmic kinases, the JAKs, for signal trans-
duction (Rawlings et al. 2004). Association of the receptor
with its respective cytokine/ligand enables the transduc-
tion of the intracellular signal by phosphorylating and ac-
tivating TFs called STATs.
As shown by interactome analysis and RNAi screens,
multiple evidences suggest that the JAK/STAT pathway
is activated in HER2 transformed MCF-10A cells. Indeed,
we found that STAT1, STAT3, and STAT5 phosphoryla-
tion increased upon overexpression of both wild-type
ErbB2 and the mutant ErbB2∗ variant used in our screens
Rodriguez-Barrueco et al.
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(Fig. 2A; Wang et al. 2006). Additionally, a reporter assay
in which luciferase expression was controlled by the pro-
moter of the bona fide endogenous STAT3 target SOCS3
(Wormald and Hilton 2004) showed a more than fourfold
increase in MCF-10A/ErbB2∗ compared with parental
MCF-10A (Fig. 2B). Consistently, we found that endoge-
nous SOCS3 mRNA levels increased (fivefold) in ErbB2∗
transformed MCF-10A cells in both 2D and 3D cultures
(Fig. 2B). Critically, STAT3 activity was exclusively
linked to increased phosphorylation and not increased
expression (Fig. 2A). Remarkably, robust activation of
STAT3 was observed when MCF-10A cells were trans-
formed with HER2 but not any common breast cancer
drivers (Supplemental Fig. S2A). Overall, these data dem-
onstrate that HER2 overexpression selectively activates
the JAK/STAT pathway.
Next, we further validated STAT3 essentiality in MCF-
10A/ErbB2∗ cells. To prevent uncontrolled cell viability
loss when silencing STAT3, we opted for a doxycycline
(Dox)-inducible RNAi system. This system coexpresses
the shRNA of interest (shRNA sequence from the pool
screens) and a red fluorescent protein (RFP) under con-
trolled conditions (addition of Dox to the culture medi-
um). The expression of the fluorescent reporter was used
for tracking shRNA-expressing cells in competition as-
says, as described above (Supplemental Fig. S1E). As be-
fore, competition assays showed a progressive loss of
MCF-10A/ErbB2∗ cells following STAT3 silencing, while
no significant effect was observed in MCF-10A cells (Fig.
2C). Loss of cell viability was not limited to standard cul-
ture conditions and was also evident in in semisolid agar
medium and 3D cultures (Fig. 2D,E). STAT3 silencing
affected MCF-10A/ErbB2∗ cell growth not only in vitro
but also in vivo, and STAT3 knockdown cells showed re-
duced tumorigenicity in orthotopic NOD scid mouse xe-
nografts (Fig. 2F). Since parental MCF-10A cells are not
tumorigenic, we used MDA-MB-231 cells to study the ef-
fect of STAT3 silencing on HER2WT cells that lack signifi-
cant STAT3 activation in vivo (Supplemental Fig. S2B). As
expected, tumors generated by transplanting MDA-MB-
231 breast cancer cells were not affected by STAT3 knock-
down (Fig. 2G; Supplemental Fig. S2C,D).
STAT3 activation in HER2+ breast cancer is mediated by
autocrine secretion of IL-6 and JAK2 activation
We next investigated the mechanisms that may mediate
aberrant STAT3 activation. By comparing gene expression
profiles of parental and HER2 transformed MCF-10A
cells, we found strong up-regulation of multiple interleu-
kin molecules and their receptors (Fig. 3A). Remarkably,
the most up-regulated interleukin (>20-fold) was IL-6,
a bona fide STAT3 activator (Rawlings et al. 2004; Murray
2007). High levels of IL-6 mRNA were reflected in a
21-fold increase in the levels of secreted IL-6 into the
culture medium (Fig. 3B). Remarkably, incubation of
MCF-10A cells with MCF-10A/ErbB2∗ conditioned medi-
um strongly induced STAT3 phosphorylation, an effect
that was abrogated by the presence of IL-6R-blocking anti-
bodies (tocilizumab) (Fig. 3C; Supplemental Fig. S3A;
Navarro-Millan et al. 2012). These data confirm previous
observations linkingHER2-mediated transformationwith
a profound transcriptional activation of inflammatory
programs (Hartman et al. 2011).
Phosphorylation and activation of STAT proteins is
mostly mediated by JAK family members (Rawlings
et al. 2004; Murray 2007). However, in cancer cells with
constitutive growth factor receptor activation, it has
also been shown that STAT proteins can also be activated
by SRCkinases (Garcia et al. 2001). Thus, we used specific
pan-inhibitors of JAK and SRC protein families as well
as the dual EGFR/HER2 inhibitor lapatinib to identify
the specific mechanism of STAT3 activation (Fig. 3D).
These experiments showed that, in breast cancer cells,
short-term inhibition of JAK proteins completely blocked
STAT3 activation, while inhibition of SRC or HER2
did not have any effect. Note that we interrogated both
MCF-10A overexpressing the oncogenic (MCF-10A/
ErbB2∗) and the wild-type HER2 (MCF-10A/ErbB2) gene
because the mutant HER2 variant has been found to be
resistant to lapatinib (Wang et al. 2006). Next, we used
specific inhibitors of different JAK family members to
identify which one of them was responsible for aberrant
STAT3 activation, revealing JAK2 as its upstream activat-
ing kinase (Fig. 3E).
Remarkably, when we studied STAT3 phosphorylation
levels (pY705) and IL-6 expression in primary breast tu-
mors using the RPPA and mRNA expression data from
theTCGAbreast cancer data set (TheCancerGenomeAt-
las Network 2012), ER−/HER+ tumors presented both the
highest levels of IL-6 expression (Fig. 3F) and the strongest
correlation between IL-6 and STAT3 phosphorylation
(Fig. 3G).
S100A8 and S100A9 are direct targets of STAT3, playing
a critical role in HER2-mediated oncogenesis
When activated, STAT3 works as a TF regulating target
gene expression on the chromatin. In order to identify rel-
evant targets of STAT3 in the ER−/HER2+ context, we
compared gene expression profiles of MCF-10A cells fol-
lowing STAT3 activation (±IL-6 in the culture medium
for 6 h) as well as of MCF-10A/ErbB2∗ cells following
shRNA-mediated STAT3 silencing (Fig. 4A; Supplemental
Fig. S4A). To identify targets that are differentially ex-
pressed following STAT3 activation, we selected genes
that fulfill two criteria: (1) They are up/down-regulated
more than twofold, with P < 0.05 in MCF-10A cells
after IL-6 exposure, and (2) they showed an opposite trend
in MCF-10A/ErbB2∗ cells following RNAi-mediated
STAT3 silencing. As expected, STAT3 as well as SOCS3
were at the top of the list. Remarkably, other top genes in-
cluded S100A8 and S100A9 (Fig. 4A; Supplemental Fig.
S4B). High mRNA levels of S100A8/9 in our MCF-10A
model led to high protein levels both in the cell extract
and secreted in the medium (Fig. 4B).
S100A8 and S100A9 are small cytoplasmic calcium-
binding proteins that heterodimerize to form a complex
(calprotectin) that is secreted into the intercellular space
(Gebhardt et al. 2006; Ehrchen et al. 2009). Although
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Figure 2. RNAi-mediated silencing of STAT3 expression reduces the tumorigenicity of HR−/HER2+ breast cancer cells. (A) Western blot
analysis of STAT1, STAT3, and STAT5 phosphorylation in MCF-10A cells and its isogenic variants overexpressing ErbB2 wild type and
the oncogenic ErbB2YVMA mutant (ErbB2∗). (B) The left panel shows a scheme of the SOCS3 promoter subcloned upstream of the firefly
luciferase reporter gene. Blue squares indicate the predicted STAT-binding sequences present in the promoter. The graph below shows the
normalized luciferase signal when the SOCS3 promoter construct was transduced into MCF-10A and MCF-10A/ErbB2∗ cells. The right
panel shows the comparison of endogenous SOCS3 expression levels between MCF-10A/ErbB2∗ and parental MCF-10A cells grown in
plastic culture plates (2D) and Matrigel (3D). (C ) Competition assay to determine the viability of MCF-10A models when STAT3 was si-
lenced. Western blot analysis of STAT3 expression after the induction of silencing shRNAs with doxycycline (Dox) is shown in the top
panel. pTRIPZ represents the control vector. The bottom panel shows the relative abundance of MCF-10A and MCF-10A/ErbB2∗ cells
expressing control or STAT3 shRNAs (RFP+) through time after they were mixed at a 50:50 ratio with nontransduced cells at the initial
time point. Dashed lines correspond to the cells where STAT3 expression has been reduced by the induction of shRNA. Colony formation
assay in agar (D) and Matrigel (E) of MCF-10A/ErbB2∗ cells expressing Dox-inducible STAT3 shRNAs or the control vector pTRIPZ. Pic-
tures were taken 6 d after plating of the cells. (F ) Tumor growth of MCF-10A/ErbB2∗-expressing control (pTRIPZ) or shRNAs against
STAT3 (shSTAT3) when orthotopically injected into the intramammary fat pad (IMFP) of immunosuppressed SCID mice (N = 5). The
box plot represents theweight of the tumors after their extraction. The left panel shows the results whenDox is administered in the drink-
ing water immediately after the transplantation. The right panel shows the tumor growth when Dox is added after the tumor reached 0.3
cc (indicated by the arrows). (G) Tumor growth and finalweightwhenMDA-MB-231 cells are othotopically injected into the IMFPof SCID
mice and Dox is administered from the day of surgery. n = 5. (∗) P < 0.05.
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Figure 3. The autocrine loop IL6–JAK2 activates STAT3 in HR−/HER2+ breast cancer cells. (A, left) The heat map shows the most up-
regulated ILs and IL receptors, comparing MCF-10A/ErbB2∗ cells and parental MCF-10A cells. (Right panel) Further validation of IL-6
and IL-6R expression by quantitative RT–PCR (qRT–PCR) is also shown. (B) Images and quantification of cytokine antibody arrays (mea-
suring 42 different cytokines) incubated for 48 h with conditioned medium of either MCF-10A or MCF-10A/ErbB2∗ cells. Cytokines
strongly secreted in MCF-10A/ErbB2∗ cells compared with MCF-10A cells are highlighted in the image by squares, and the same color
code is used in the bar chart. The names of these secreted cytokines are shown above the bars. (C ) Western blot analysis of STAT3 phos-
phorylation in MCF-10A cells when incubated with MCF-10A/ErbB2∗ conditioned medium for 1 h and inhibition of its activation when
the cells are simultaneously treated with 50 µg/mL tocilizumab. (D) STAT3 phosphorylation after treatment of MCF-10A/ErbB2∗ and
MCF-10A/ErbB2 with either 1 µM pan-Src inhibitor-I, 1 µM pan-JAK inhibitor-I, or 1 µM lapatinib for 8 h was measured by Western
blot. (E) Determination of STAT3 phosphorylation inMCF-10A/ErbB2∗ cells after treatmentwith inhibitors of different JAK familymem-
bers for 24 h. All inhibitors were used at 1 µM concentration except CEP33779, which was used at 5 µM. The table below indicates the
specificity of each of the inhibitors. (F ) Box plot representing the expression of IL-6 in primary breast cancers classified according to their
estrogen receptor (ER) and HER2 status. For F andG, the data were obtained from the RPPA data set of the TCGA. Every dot represents a
sample, and the dashed line indicates the slope of the correlation. (G) Correlation between STAT3 phosphorylation and IL-6 levels in each
subtype of primary breast sample analyzed.
Targeted therapy for HR−/HER2+ breast cancers
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Figure 4. S100A8 and S100A9 are transcriptional targets of STAT3. (A) The heatmap shows genes transcriptionally up-regulated inMCF-
10A cells when STAT3 is activated by 50 µg/mL IL-6 for 6 h and down-regulated in MCF-10A/ErbB2∗ cells when STAT3 is silenced with
two independent shRNAs. (B) Western blot analysis of S100A8 and S100A9 expression in MCF-10A and MCF-10AErbB2∗ whole extracts
as well as in their 48-h conditioned medium. (C ) Box plot representing the correlation between S100A9mRNA expression and HER2 im-
munohistochemistry score in primary breast cancers. Data were obtained from aMETABRIC data set. (D) Distribution of S100A9mRNA
expression in primary breast cancers according to tumor subtype as determined by ER and HER2 status. The slope of the correlation is
shown by the dashed line and is indicated at the top. (E) Correlation between S100A9 mRNA levels and STAT3 phosphorylation in
the primary breast cancer subtype. Datawere obtained from the TCGA data set. (F ) Ten-year Kaplan-Meier survival curve of breast cancer
patients classified according to the S100A9 expression in the tumor. Data were obtained from the METABRIC data set. S100A9 levels
above and under the median are considered high and low, respectively. (G) Analysis by Western blot of S100A8 and S100A9 levels
when STAT3 expression is silenced by Dox-inducible shRNAs. (H) SOCS3, S100A8, and S100A9 promoters were cloned in a luciferase
reporter vector. HEK293T cells were transfected with these constructs along with vectors expressing Renilla luciferase for normalization
purpose. The bar graph represents the normalized levels of luciferase expression from each of these constructs when STAT3was activated
for 6 h with 50 µg/mL IL-6 in the presence of different doses of the dual JAK1/2 inhibitor ruxolitinib. (I ) Determination of STAT3 binding
to the S100A8 and S100A9 promoters was performed by chromatin immunoprecipitation (ChIP) assay using MCF-10A cells expressing
V5-tagged STAT3. Blue squares in the promoter indicate putative STAT-binding sites, and the bars show the enrichment measured by
qRT–PCR after STAT3-V5 immunoprecipitation of cells incubated for 30 min with 50 µg/mL IL-6. (∗) Statistical significance < 0.05.
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they have been mainly studied in the context of the im-
mune system, S100A8/9 have been found to be up-regulat-
ed in multiple solid tumors and associated with poor
prognosis (Arai et al. 2008; Kawai et al. 2011; Grebhardt
et al. 2014).
Next, we analyzed the METABRIC data to investigate
whether overexpression of S100A8/9 was observed in
ER−/HER2+ primary breast tumors. These studies re-
vealed that mRNA levels of S100A8 and S100A9 are
strongly correlated (r = 0.94), suggesting coregulation (Sup-
plemental Fig. S4C). Furthermore, mRNA expression of
S100A8/9was strongly correlatedwithHER2 pathological
status (Fig. 4C). Importantly, ER−/HER2+ tumors present-
ed the highest S100A8/9 expression (Fig. 4D) as well as the
highest correlation between STAT3 phosphorylation and
S100A8/9 mRNA expression (the RPPA data set from
the TCGA breast cancer studywas used here) (Fig. 4E). Re-
markably, high S100A8/9 expression was associated with
lower breast cancer patient survival (Fig. 4F).
Taken together, these data suggest that expression of
S100A8/9 in ER−/HER2+ tumor cells is intimately linked
to aberrant STAT3 activation. To validate the dependency
of S100A8 and S100A9 expression on STAT3 activity,
we performed RNAi-mediated STAT3 silencing in
MCF-10A/ErbB2∗ cells. As expected, STAT3 knockdown
strongly reduced S100A8 and S100A9 expression (Fig.
4G). Both the S100A8 and S100A9 promoters present sev-
eral predicted STAT-binding sequences. Thus, we cloned
the S100A8, S100A9, and SOCS3 (positive control) pro-
moters to drive expression of a luciferase reporter (Supple-
mental Fig. S4D) and evaluated reporter gene induction
upon STAT3 activation. HEK293T cells transfected with
the reporters showed strong induction of luciferase ex-
pression after addition of IL-6 to the medium (Fig. 4H;
Supplemental Fig. S4E). Importantly, the effect was fully
abrogated when STAT3 activation was prevented by the
JAK1/2 inhibitor ruxolitinib (Fig. 4H; Mascarenhas and
Hoffman 2012; Mesa et al. 2012). To further investigate
whether regulation of S100A8 and S100A9 occurs by di-
rect binding of STAT3 to their promoters, we performed
chromatin immunoprecipitation (ChIP) assays. For this,
we first engineered MCF-10A cells expressing V5-tagged
STAT3. After checking that STAT3-V5 behaves identical-
ly to endogenous STAT3 (it is enriched in the nucleus af-
ter IL-6 exposure) (Supplemental Fig. S4F), STAT3-V5 was
immunoprecipitated from MCF-10A cells cultured in the
absence/presence of IL-6. Next, the presence of STAT3 in
S100A8 and S100A9 promoters was evaluated by quanti-
tative PCR (qPCR). These studies revealed a significant
enrichment of STAT3 in both promoters upon IL-6-medi-
ated STAT3 activation (Fig. 4I).
Since S100A8/9 are part of the transcriptional program
up-regulated by STAT3 in ER−/HER2+ mammary tumors,
we asked whether S100A8/9 are relevant for the essential
role of STAT3 in these cancer cells. Remarkably, shRNAs
targeting both S100A8 and S100A9 were also positive hits
in our RNAi screen (Fig. 5A). To study the role of S100A8
and S100A9, we first engineeredMCF-10A/ErbB2∗ cells to
express shRNAs targeting both genes under inducible
conditions (Supplemental Fig. S5A). We then studied
how S100A8/9 silencing impacts the tumorigenic poten-
tial of these cells. S100A8/9 silencing phenocopied the le-
thal effect induced by STAT3 inhibition in vitro (Fig. 5B,
C) and in vivo when MCF-10A/ErbB2∗ variants were
orthotopically injected in NOD scid mice (Fig. 5D).
Next, we reasoned that, if STAT3-dependent lethality
in MCF-10A/ErbB2∗ cells is mediated at least in part by
loss of S100A8/9 expression, then re-expression of these
genes should rescue the phenotype. To test this scenario,
we first transduced MCF-10A/ErbB2∗-expressing STAT3
targeting shRNAs with viral constructs expressing
S100A8 and S100A9. As these viral constructs coexpress
the cDNAs and fluorescent reporters, we were able to
use FACS to separate the transduced cells in bins express-
ing different amounts of S100A8 and S100A9 based on
fluorescence intensity (Supplemental Fig. S5B). Finally,
we also selected sorted cells expressing S100A8 and
S100A9 at the levels found in parental MCF-10A/ErbB2∗
cells (Supplemental Fig. S5B). When the tumorigenic po-
tential of these cells was assayed, we found that re-ex-
pression of S100A8/9 restored the tumorigenic potential
of MCF-10A/ErbB2∗ cells expressing STAT3 targeting
shRNAs in vitro (Fig. 5B) and in vivo (Fig. 5D).
Because S100A8/9 are proinflammatory cytokines that
influence the recruitment of immune cells (Gebhardt
et al. 2006; Ehrchen et al. 2009), in order to eliminate, as
much as possible, any contribution of the immune system
in the growth of the tumor cells, we repeated the above
studies using NOD scidγ mice (deficient in B and T cells,
macrofages, NK cells, and complement). These experi-
ments confirmed the importance of the autocrine sti-
mulus mediated by S100A8/9 (Fig. 5E). Finally, we also
asked whether up-regulation of S100A8/9 alone in non-
transformed cells is able to transform them. Experimental
up-regulation of S100A8 and S100A9 to the levels ob-
served in HER2 transformed MCF-10A cells by using the
viral cDNA constructs described above did not provide at-
tachment-independent growth abilities to MCF-10A cells
(Supplemental Fig. S5C).
S100A8 and S100A9 play a pivotal role in HER2-
mediated oncogenesis by promoting key proliferative
and survival signal transduction pathways
After demonstrating the critical role of S100A8/9 in
HER2-mediated oncogenesis in our HR−/HER2+ model,
we decided to investigate the specific mechanism. Expo-
sure to S100A8/9 has been shown to activate canonical
signal transduction pathways that are involved in tumor-
igenesis by increasing proliferation, resistance to stress,
and protein synthesis (Gebhardt et al. 2006; Hermani
et al. 2006; Ichikawa et al. 2011; Acharyya et al. 2012).
As the activation of particular signaling is often context-
dependent, we first decided to evaluate the activation of
these pathways in our model after cells are exposed to re-
combinant S100A8/9 protein.
In order to expose cells to physiologic S100A8/9 protein
levels, we first measured the amount of S100A8/9
proteins in the culture medium of MCF-10A/ErbB2∗
cells. Conditioned media with different numbers of cells
Targeted therapy for HR−/HER2+ breast cancers
GENES & DEVELOPMENT 1639
growing exponentially for 48 hwere concentrated, and the
levels of S100A8/9 proteins were estimated by titrating
recombinant protein through a standard curve (Supple-
mental Fig. S6A). This study revealed that ∼75–150 ng of
S100A8 and S100A9 was present in the conditioned
media per 1 × 105 cells (Supplemental Fig. S6A). When
an equivalent amount of recombinant proteins was added
to the culture medium of MCF-10A cells, we observed a
robust increase in the phosphorylation levels (activation)
of ERK1/2 and AKT and a minor effect on phosphor-
P70S6K (Fig. 6A). Furthermore, MCF-10A cell prolife-
ration increased (Fig. 6B). It is well established that activa-
tion of the above-mentioned pathways is directly achieved
by EGFR/HER familymembers without the need for auto-
crine stimulation (Moasser 2007). Thus, it was important
to investigate whether the activation mediated by the
S100A8/9 autocrine mechanism is a way to amplify
the signal and achieve the high levels observed in HER2+
cells or is simply redundant. To answer this question,
we blocked S100A8/9 activity in MCF-10A/ErbB2∗ cells
Figure 5. S100A8 and S100A9 play a critical role in HER2-mediated oncogenesis. (A) Schematic representation of the rank of shRNAs
according to their Z-scores in the screen. Positions of the shRNAs that target STAT3 (blue), S100A8 (orange), and S100A9 (green) are
shown. (B) Colony formation assay in agar of MCF-10A/ErbB2∗ cells transduced with control vector (pTRIPZ), shRNA against STAT3
(shSTAT3), shRNAs against S100A8 and S100A9 (shS100A8/9), or shRNA against STAT3, where the expression of S100A8 and
S100A9 has been restored experimentally by transduction of c-DNAs (shSTAT3 + S100A8/9-cDNA). All vectors expressing shRNAs
were Dox-inducible. The chart bars represent the quantification of the number of colonies normalized to the pTRIPZ control. (C ) Growth
in ECM-Matrigel of cells fromB. Quantification of the effect of gene silencing in the growth of the acini is provided in the graphs showing
the size distribution of 50 acini. (∗∗∗) P < 10−5. (D) The top panel shows the growth of tumors (average ± SD) when the different variants of
MCF-10A/ErbB2∗ cells described in B were injected into the IMFP of NOD scid mice. n = 5. (E) The same experiments performed in D
when the cells were injected into the IMFP of NOD scidγ mice. n = 6. The box plot represents the final weight of the dissected tumors,
and a representative picture of each injected mouse is shown. The arrow indicates when 2 mg/mL Dox was added to the drinking water.
(∗) P < 0.05.
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Figure 6. S100A8 and S100A9 activate signal transduction pathways involved in tumorigenesis. (A) Western blot analysis of phosphor-
ylation levels of AKT, ERK1/2, and p70S6K in MCF-10A cells incubated with increasing doses of recombinant S100A8 and S100A9 for 6
h. (B) Increase in the number of MCF-10A cells incubated with different doses of S100A8/9 for 48 h as measured with Cell Titer Glo. The
fold changewas normalized to untreated cells. (∗) P < 0.05 (C ) Phosphorylation levels of HER2, STAT3, AKT, ERK1/2, and p70S6K inMCF-
10A/ErbB2∗ cells after treatment with increasing doses of the S100A9 inhibitor tasquinimod for 48 h. (D) Schematic representation of the
double autocrine loop in HR−/HER2+ breast cancer cells. FDA-approved inhibitors against different components of the pathway are indi-
cated in red. (E) TheWestern blot shows the phosphorylation levels of STAT3,AKT, and ERK1/2 aswell as S100A8 and S100A9 levels after
treatmentwith 50 µg/mL tocilizumab, 1 µM ruxolitinib, or 10 µM tasquinimod for 48 h. (F ) Quantification of Annexin V+ cells by FACS in
MCF-10A andMCF-10A/ErbB2∗ cells incubated with 50 µg/mL tocilizumab, 1 µM ruxolitinib, or 10 µM tasquinimod for 48 h. (∗) P < 0.05
(G) Immunohistochemical analysis of pSTAT3, Ki67, Caspase3, pAKT, and pERK1/2 levels inMCF-10A/ErbB2∗ orthotopic tumors. Cells
were injected into the IMFPof SCIDmice and allowed to growuntil they reached a volumeof 0.3 cc, when the treatmentwas administered
for 4 d as follows: 2 mg of tocilizumab per mouse, twice per week; 90 mg/kg ruxolitinib twice per day; or 10 mg/kg tasquinimod per day.
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using the specific S100A9 inhibitor tasquinimod (Dalrym-
ple et al. 2007, 2012). We found that, despite having the
same HER2+ phosphorylation levels as untreated cells,
blocking S100A8/9 significantly reduced the activation
levels of AKT, while less pronounced effects were ob-
served for ERK1/2 and P70S6K (Fig. 6C).
Our studies suggest the existence of a critical double au-
tocrine stimulus in HR−/HER2+ breast cancer cells. The
first stimulus is defined by the secretion of IL-6 to activate
STAT3 through the canonical JAK pathway. Once activat-
ed, STAT3 induces up-regulation of the S1008/9 dimer,
which is secreted and augments AKT activation and, to
a lesser extent, ERK1/2 and P70S6K (Fig. 6D). Importantly,
several compounds targeting key players of this double au-
tocrine loop are already available in the clinic, providing
exciting therapeutic opportunities (Fig. 6D; Supplemental
Fig. S6B). Tocilizumab is a humanized antibody against
the IL-6R. It is FDA-approved for the treatment of rheuma-
toid arthritis (RA) (Patel and Moreland 2010; Navarro-
Millan et al. 2012). Ruxolitinib is a JAK1/2 dual inhibitor
that has been recently FDA-approved to specifically treat
patients with myelofibrosis (Mascarenhas and Hoffman
2012;Mesa et al. 2012). Tasquinimod binds to and inhibits
the interactions of S100A9 and is actively being investi-
gated for the treatment of solid tumors, mostly prostate
cancers (Dalrymple et al. 2007, 2012).
Thus, we next studied the use of these inhibitors to re-
duce the levels of S100A8 and S100A9 proteins as well as
the activation of the signaling cascades described above.
As expected, treating MCF-10A/ErbB2∗ cells with tocili-
zumab or ruxolitinib strongly inhibited the expression
of S100A8 and S100A9 (Fig. 6E), and each of the three in-
hibitors significantly attenuated phosphor-AKT levels.
Remarkably, treatment with these inhibitors was asso-
ciated with increased apoptosis in MCF-10A/ErbB2∗ cells
compared with the parental MCF-10A line (Fig. 6F). Im-
portantly, we observed comparable results in vivo when
orthotopic models of MCF-10A/ErbB2∗ were treated with
the same inhibitors (Fig. 6G; Supplemental Fig. S6C).
Inhibition of IL-6R/JAK2/S100A9 represents a novel
target for patient-oriented therapies in HR−/HER2+
breast cancers
The studies described above suggest that inhibition of
IL-6R/JAK2/S100A9 represents a novel, mechanistically
motivated anti-cancer strategy in HR−/HER2+ breast can-
cers. In order to further investigate this possibility, we
completed a series of in vitro and in vivo studies to evalu-
ate tumor growth treatment with the above-described in-
hibitors. First, we selected a set of nine additional breast
cancer cell lines, representing the four subtypes (HR+/
HER2−, HR+/HER2+, HR−/HER2−, and HR−/HER2+) (Fig.
7A; Supplemental Fig. S7A). In these cells, we studied
STAT3 phosphorylation as well as S100A8 and S100A9
protein expression. Consistent with our model, HR−/
HER2+ cell lines presented both the highest phospho-
STAT3 levels and the highest S100A8 and S100A9 expres-
sion (Fig. 7A). Furthermore, exposing HR−/HER2+ HCC-
1954 cells to tocilizumab, ruxolitinib, and tasquinimod
reduced the levels of p-STAT3, P-AKT, and S100A8/9,
as seen in the MCF-10A/ErbB2∗ model (Supplemental
Fig. S7B).
All of these cell models were then plated in Matrigel
and individually treated with tocilizumab, ruxolitinib,
and tasquinimod. As expected, growth of HR−/HER2+
cells was significantly affected by these treatments, while
minor effects were observed in the remaining cells lines
(Fig. 7B shows only HR−/HER2+ cell lines; Supplemental
Fig. S7C,D shows the full set). Interestingly, in addition
to the HR−/HER2+ models, HCC-70 was the only cell
line that was strongly affected when treated with ruxoliti-
nib.Thiswas not surprising, as these cells have high levels
of p-STAT3 (Fig. 7A). Finally, to transition our studies to
an in vivo context,MCF-10A/ErbB2∗ cells were orthotopi-
cally transplanted into the mammary glands of NOD scid
mice and individually treated with each of the three in-
hibitors. As seen in vitro, treatment with tocilizumab,
ruxolitinib, and tasquinimod significantly reduced the
tumorigenic potential of MCF-10A/ErbB2 cells in vivo
(Fig. 7C; Supplemental Fig. S7E). To further complete
our preclinical studies, seven different orthotopically in-
jected cell lines in NOD scid mice representing the four
subtypes, a patient-derived HR−/HER2+ xenograft, and a
transgenic HER2+ breast cancer mouse model, FVB-Tg
(MMTV-Erbb2)NK1Mul/J (http://jaxmice.jax.org/strain/
005038.html), were treated with ruxolitinib . HER2+mod-
els were also treated with the humanized anti-HER2 anti-
body trastuzumab (Lewis Phillips et al. 2008) and the
combination of trastuzumab plus ruxolitinib. For these
in vivo studies, ruxolitinib was selected over tasquinimod
and tociluzumab because it is already FDA-approved for
cancer treatment. These studies confirmed that response
to ruxolitinib as a sole anti-cancer agent in all engrafted
HR−/HER2+ cells (MCF-10A/ErbB2∗, HCC-1954, and the
patient-derived xenograft [PDX]) was statistically signifi-
cant (Fig. 7D,E; Supplemental Fig. S7G,H). Interestingly,
the HR+/HER2+ line MDA-MB-361 showed minimal re-
sponse (not statistically significant) to individual treat-
ment with ruxolitinib and trastuzumab, which became
statistically significant when the animals were treated
in combination. The enhanced anti-tumor effect when
trastuzumab and ruxolitinib were used in combination
was confirmed in both HR+/HER2+ and HR−/HER2+ mod-
els in vivo (Fig. 7D,E; Supplemental Fig. S7G,H). As seen
in vitro, the HCC-70 model also responded to ruxolitinib
treatment in vivo.
Transgenic FVB-Tg(MMTV-Erbb2)NK1Mul/J females
developed multifocal tumors after pregnancy, and, con-
sistent with the xenograft models, we observed that
treatmentwith ruxolitinib reduced both the number of tu-
mors formed and the growth of individual tumor masses
(Fig. 7F).
Discussion
Breast cancer is not a homogeneousmalignancy but rather
a heterogeneous group of tumor diseases (Bertos and
Park 2011). Hyperactivation of HER2 has been classically
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Figure 7. Tocilizumab, ruxolitinib, and tasquinimod are efficient anti-cancer drugs in HR−/HER2+ breast cancer cells. (A) Western blot
analysis of STAT3 phosphorylation as well as S100A8 and S100A9 levels in a panel of breast cancer cell lines. HR and HER2 status is in-
dicated at the bottom. (B) Growth in ECM-Matrigel of HR−/HER2+ breast cancer models (MCF-10A/ErbB2∗, HCC-1954, and SUM-190)
when treated with inhibitors. Pictures were taken after 6 d of treatment with 200 µg/mL tocilizumab, 1 µM ruxolitinib, and 10 µM tas-
quinimod. A complete series of all 11 cell lines is shown in A, and additional drug doses are shown in Supplemental Figure S7. Quanti-
fication of the effect of drug treatment in the growth of the cells is provided in the graphs showing the size distribution of 50 acini. (∗∗∗) P <
10−5. (C ) Tumor growth of MCF-10A/ErbB2∗ cells injected into the IMFP of SCID mice. n = 6. Treatment was administrated as follows:
2 mg of tocilizumab per mouse, twice per week; 90 mg/kg ruxolitinib, twice per day; or 10 mg/kg tasquinimod per day. Representation
of the growth curves generated by the injection of breast cancer cell lines (D) or a patient-derived xenograft (PDX) (E) into the IMFP of
SCIDmice. n = >6 for all animal experiments shown inD and E. (F ) Three-month-old transgenic FVB-Tg(MMTV-Erbb2)NK1Mul/J female
animalsweremated and randomly assigned a treatment cohort when the absolute tumormass reached 100mm3. The left panel shows the
growth of the tumor masses as absolute tumor volume per mouse (multifocal masses). The right panel shows the growth kinetics of in-
dividual tumors. Three individual animals were analyzed per cohort. For all panels, mice were treated with herceptin (one loading shot of
30 mg/kg followed by administration of 15 mg/kg twice per week), ruxolitinib (90 mg/kg, twice per day), or the combination of both. The
black arrows indicate the point when the treatment was started (tumors reached 0.3 cc). (∗) P < 0.05, (∗∗) P < 0.01, (∗∗∗) P < 0.001.
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considered one of the determinants that define ∼20% of
all breast cancers, and, consequently, HER2+ breast can-
cers have been managed in the clinic as a homogeneous
group (Hynes and Lane 2005; Lemmon and Schlessinger
2010). However, emerging evidence has challenged this
view, revealing important intrinsic differences associated
with HR status (Perou et al. 2000; Paluch-Shimon et al.
2009; Sotiriou and Pusztai 2009; Vaz-Luis et al. 2012).
We and others have previously described screening
strategies based on genetic (Silva et al. 2008; Marcotte
et al. 2012) and small molecule (Gupta et al. 2009; Heiser
et al. 2012) inhibitors aimed to identify the Achilles’ heel
of tumor cells based on specific aspects of their biology.
Similarly, we showed that analysis of regulatory networks
can identify MR genes that are necessary and sufficient
for tumor survival (Carro et al. 2010; Piovan et al. 2013;
Aytes et al. 2014). Here, we describe the design and re-
sults of the first integrative analysis that combines
both methodologies to identify novel therapeutic targets
for HR−/HER2+ breast cancers. Our studies identified
that HR−/HER2+ breast cancers robustly activate the
IL-6–JAK2–STAT3–calprotectin cascade. Importantly,
we also demonstrated that the tumorigenic potential of
these cells is dependent on the activation of this autocrine
cascade.
Activation of STAT3 in metastatic progression is well
established and has been associated with myeloid cell re-
cruitment (Chang et al. 2013), angiogenesis (Chang et al.
2013), epithelial–mesenchymal transition (Wendt et al.
2014), and migration (Barbieri et al. 2010a). However, its
potential role in the maintenance of breast cancer cell ho-
meostasis is not clear. While STAT3 is dispensable to ini-
tiate tumorigenesis in HER2-driven mouse mammary
models (Barbieri et al. 2010b), blocking STAT3 signaling
in some cancer cell models compromises their tumorige-
nicity (Marotta et al. 2011; Chang et al. 2013). Arguably,
poor understanding of the molecular determinants that
define STAT3 activation as an essential hub in some cells
but not in others prevents us from considering therapies
targeting its activation.
Here, we report that HR−/HER2+ breast cancers are
especially sensitive to inhibition of STAT3 activation.
Mechanistically, we identified the downstream targets
of STAT3 (S100A8 and S100A9) as responsible, at least
partially, for this sensitivity. S100A8 and S100A9 are
calcium-binding proteins that heterodimerize, forming
a complex called calprotectin that is secreted (Gebhardt
et al. 2006; Ehrchen et al. 2009). While the role of
S100A8/9 as proinflammatory mediators secreted by im-
mune cells is well documented, S100A8/9 proteins are
also found up-regulated in multiple solid tumors and as-
sociated with poor prognosis characteristics (Arai et al.
2008; Kawai et al. 2011; Grebhardt et al. 2014). Indeed, au-
tocrine and paracrine exposure to calprotectin activates
key signaling pathways involved in tumorigenesis (Geb-
hardt et al. 2006; Hermani et al. 2006; Ichikawa et al.
2011; Acharyya et al. 2012). Our data using immuno-
compromised mouse models lacking all major immune
cells (NOD scidγ) reveal that, in the context of HR−/
HER2+ breast cancers, S100A8/9 secreted by the tumor
cells is an important mediator of tumorigenesis that
increases the phosphorylation of AKT and, to a lesser ex-
tent, ERK.
How can the above-mentioned observations explain the
sensitivity of HR−/HER2+ breast cancer cells to inhibition
of the IL-6–JAK2–STAT3–calprotectin cascade? Aberrant
AKT activity is a key event commonly seen in human
cancers that positively impacts most cancer hallmarks,
including cell cycle, survival, metabolism, motility,
genomic instability, angiogenesis, and inflammatory cell
recruitment (Testa and Tsichlis 2005; Fruman and Rom-
mel 2014). AKT is directly stimulated by activation of
growth factor receptors, including HER2, through canon-
ical PI3K–PIP3 signals. Additionally, cross-talkwith other
pathways and feedback loops modulate the final activity
of AKT (Testa and Tsichlis 2005; Fruman and Rommel
2014). Our results suggest that overexpression and secre-
tion of S100A8 and S100A9, as detected in HR−/HER2+
cells, also contribute to aberrant AKT activity. It is thus
plausible that inhibiting S100A8/9 secretion may reduce
AKT activity (despite an otherwise unchanged stimulus
from oncogenic HER2) to a point that becomes critical
for these cancer cells. Although several receptors for
S100A8/9 have been identified (RAGE [Turovskaya et al.
2008], TLR4 [Kallberg et al. 2012], and EMMPRIM [Hibino
et al. 2013]), how the signal is transmited to AKT is not
characterized. It will be important to dissect the signaling
pathways that connect S100A8/9 with AKT, as additional
therapeutic alternatives may emerge.
An additional consideration regarding the sensitivity
of HR−/HER2+ cells is that STAT3 has been found activat-
ed in stem cell-like breast cancer cells, and its inhibition
was shown to reduce their viability (Marotta et al. 2011;
Chung et al. 2014). Thus, the anti-tumor response ob-
served may also be a reflex of the inhibition of the stem
cells inside HR−/HER2+ cancers. Although HR−/HER2+
cancer cells were the most sensitive to the inhibition
of the IL-6–JAK2–STAT3–calprotectin axis, we observed
that STAT3 blockade with ruxolitinib also affects the
growth of a HR+/HER2+ model—especially when com-
bined with anti-HER2 therapy—as well as some breast
cancer cells with high levels of p-STAT3 (see Fig. 7D; Sup-
plemental Fig. 7G). Remarkably, the link between HER2,
STAT3, and stem cell-like cells has also been described in
HR+ breast cancers, which could explain this effect (Mar-
otta et al. 2011; Chung et al. 2014). Overall, the studies de-
scribed here unveil the IL-6–JAK2–STAT3–calprotectin
cascade as an Achilles’ heel of HR−/HER2+ tumors. Im-
portantly, our preclinical studies demonstrating anti-
cancer activity of FDA-approved drugs (ruxolitinib and
tociluzumab) as well as of a compound that is currently
being evaluated in clinical trials (tasquinimod) open new
avenues for a rapid transition of our findings to the clinic.
Indeed, our data serve as the basis for investigating the
combination of ruxolitinib and trastuzumab in a phase
I/II, multicenter trial in patients with metastatic breast
cancer that has progressed on prior HER2 targeted therapy
(ClinicalTrials.gov identifier NCT02066532). If a clinical
benefit is identified, inhibition of the IL-6–JAK–STAT3–
calprotectin axis by ruxolitinib would represent a novel,
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non-chemotherapy-containing, orthogonal anti-cancer
strategy for HER2+ breast cancers.
Materials and methods
Pooled shRNA screening
MCF-10A andMCF-10A/ErbB2∗ cells were infectedwith a pool of
virus generated from the Open BiosystemGIPZ lentiviral human
shRNA library that comprises 58,493 shRNA targeting 18,651
genes. After infection, cells were cultured in triplicate in standard
plastic plates for 10 doubling times or embedded in ECM-Matri-
gel for 1 wk. In addition, MCF-10A/ErbB2∗ cells were injected
in triplicate into the intramammary fat pad (IMFP) of immuno-
compromised mice to perform the in vivo screening. Experimen-
tal details are described in Rodriguez-Barrueco et al. (2013). Data
analysis details are described in Yu et al. (2013).
Data-driven network reconstruction of breast cancer
Weused a data-driven approach,ARACNe, to reconstruct a breast
cancer interactome from 359 TCGA breast cancer gene expres-
sion profiles. We then applied ARACNe against 1597 probes
corresponding to 780 TFs to establish a TF-centered interactome
and against 6434 probes for 2453 signalingmolecule genes to con-
struct a SP-focused network. The parameters of the algorithm
were configured as follows: P-value threshold, P = 1 × 10−7; DPI
tolerance, e = 0; and number of bootstraps, NB = 100. We used
the adaptive partitioning algorithm for mutual information
estimation.
Gene expression arrays
For gene expression arrays, MCF-10A and MCF-10A/ErbB2∗
RNAs were extracted using RNeasy extraction kits and labeled
using the low-input QuickAmp labeling kit (Agilent, no. 5190-
2331) following the manufacturer’s instructions. Finally, labeled
RNAs were hybridized on an Illumina HT12v3 microarray. The
experiment was performed with an n = 6.
MCF-10A cells were treated with 50 µg/mL IL6 for 1 h. In par-
allel, MCF-10A/ErbB2∗ infected with inducible shRNAs against
STAT3 were incubated with 100 ng/mL Dox for 5 d. RNA from
each condition was extracted with RNeasy extraction kit, la-
beled, and hybridized on a humanGE 4x44K version 2microarray
kit (Agilent, no. G4845A).
Gene expression data have been uploaded, and the Gene Ex-
pression Omnibus accession number assigned is GSE62251.
MR analysis
We interrogated the TCGA breast cancer interactomes and
applied MARINa to identify key master transcriptional or sig-
naling drivers for MCF-10A/ErbB2∗ cells or HR−/HER2+ breast
cancer samples in TCGA orMETABRIC data. For the gene set en-
richment analysis method in MARINa, we applied the “max-
mean” statistic to score the enrichment of the gene set and
used a sample permutation to build the null distribution for stat-
istical significance.
Viral production and infection
Lentiviral productionwas achieved by transfecting phoenix pack-
aging cells with jet-PEI (Polyplus, #101-10N) in combinationwith
the lentiviral plasmids (shRNA listed below, pLOC_S100A8, and
pLX304-Blast-V5_STAT3) and the pCMV-dR8.91 and pMD.G
helper plasmids at a ratio of 2:1:1, respectively (Rodriguez-Bar-
rueco et al. 2013). The same conditionswere employed to produce
retroviral particles by combining the retroviral plasmids (pBABE-
HERYVMA and pLPCX-RFP_S100A9) with the retroviral helper
plasmids Psi and VSVg. A detailed protocol is in the Supplemen-
tal Material as well as precious publications (Rodriguez-Barrueco
et al. 2013).
S0CS3, S100A8, and S100A9 promoter cloning
and luciferase assay
To measure luciferase activity, phoenix cells were plated at 70%
confluence in 96-well plates. Twenty-four hours later, cells were
transfected with 50 ng of pGL3 constructs containing the pro-
moter sequences in combination with a Renilla normalization
control using jet-PEI transfection reagent. After 24 h, relative lu-
ciferase units (RLU) were measured using the Dual-Glo Lucifer-
ase assay system (Promega, #E2949).
Soft agar colony formation assay
Cells were plated in semisolid medium as follows: 35-mm plates
were layered with 0.6% agar (Spectrum Chemical, AG110) and
medium, and 5.0 × 103 cells permilliliter were seeded in triplicate
in the second layer of 0.3% agar and medium and cultured in
the appropriate growth medium. Colonies were stained with 1
mg/mL MTT (Sigma, M2128) after 3 wk of incubation, photo-
graphed, and counted, and the average ± standard deviation was
represented.
3D basement membrane cultures
Wells in 24-well low-attachment plates (Corning, no. 3473) were
precoated with a layer of 200 µL of 100% ECM-Matrigel per well
(BD Biosciences, no. 354230) and allowed to gel at 37°C. Cells
were trypsinized and diluted at densities of 1 × 105 or 2 × 105 cells
per milliliter in assay medium (DMEM/F12 supplemented with
5% HS, 0.5 µg/mL hydrocortisone, 100 ng/mL cholera toxin,
10 µg/mL insulin, 4 ng/mL EGF, 5% ECM-Matrigel). Fresh assay
mediumcontaining the drugs at the indicated concentrationswas
added every day. Pictures were taken after 6 d of treatment.
Mice
Animal maintenance and experiments were performed in accor-
dance with the animal care guidelines and protocols approved
by the Columbia University animal care unit. Eight-week-old fe-
male NOD.CB17-Prkdcs SCID mice (Harlan) were injected with
5 × 106 cells resuspended in Matrigel (BD Biosciences):normal
growth medium (1:1) into the fat pad mammary gland. Dox was
added to drinking water at a final concentration of 2.0 mg/mL.
Tumor growth was monitored twice a week with calipers at
the site of injection. Animals were sacrificed when tumor size
reached 1.5-cm diameter.
ChIP
MCF-10A and MCF-10A/STAT3-V5 cells (untreated cells and
cells treated with 50 µg/mL IL6 for 30 min) were grown to
80%–90% confluency in 150-mm culture dishes. After washing
with PBS, cells were fixed and cross-linked using a truChIP
HighCell chromatin shearing kitwith SDS shearing buffer (Cova-
ris, no. 010128) following the manufacturer’s instructions.
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The next day, anti-V5-conjugated beads were resuspended in
1 mL of blocking buffer. Nuclear extracts (100 µL) were added
to the bead solution and incubated overnight at 4°C on a rotator.
After 12 h, beads were collected, and DNAwas obtained by stan-
dard protocols (detailed in the Supplemental Material).
Acknowledgments
This work was supported by National Institutes of Health grant
R01/EUREKA R01CA153233 and the American Association
for Cancer Research-Stand up to Cancer award (J.M.S.) and the
National Cancer Center (R.R.-B.).
References
Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris
PG, Manova-Todorova K, Leversha M, Hogg N, Seshan VE,
et al. 2012. A CXCL1 paracrine network links cancer chemo-
resistance and metastasis. Cell 150: 165–178.
Arai K, Takano S, Teratani T, Ito Y, Yamada T, Nozawa R. 2008.
S100A8 and S100A9 overexpression is associated with poor
pathological parameters in invasive ductal carcinoma of the
breast. Curr Cancer Drug Targets 8: 243–252.
Aytes A, Mitrofanova A, Lefebvre C, AlvarezMJ, Castillo-Martin
M, Zheng T, Eastham JA, Gopalan A, Pienta KJ, Shen MM,
et al. 2014. Cross-species regulatory network analysis identi-
fies a synergistic interaction between FOXM1 and CENPF
that drives prostate cancer malignancy. Cancer Cell 25:
638–651.
Barbieri I, Pensa S, Pannellini T, Quaglino E, Maritano D, Dema-
ria M, Voster A, Turkson J, Cavallo F, Watson CJ, et al. 2010a.
Constitutively active Stat3 enhances neu-mediatedmigration
andmetastasis in mammary tumors via upregulation of Cten.
Cancer Res 70: 2558–2567.
Barbieri I, Quaglino E, Maritano D, Pannellini T, Riera L, Cavallo
F, Forni G, Musiani P, Chiarle R, Poli V. 2010b. Stat3 is re-
quired for anchorage-independent growth and metastasis but
not for mammary tumor development downstream of the
ErbB-2 oncogene. Mol Carcinog 49: 114–120.
Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R,
Califano A. 2005. Reverse engineering of regulatory networks
in human B cells. Nat Genet 37: 382–390.
BerclazG, AltermattHJ, RohrbachV, SiragusaA,Dreher E, Smith
PD. 2001. EGFR dependent expression of STAT3 (but not
STAT1) in breast cancer. Int J Oncol 19: 1155–1160.
Berishaj M, Gao SP, Ahmed S, Leslie K, Al-Ahmadie H, Gerald
WL, Bornmann W, Bromberg JF. 2007. Stat3 is tyrosine-phos-
phorylated through the interleukin-6/glycoprotein 130/Janus
kinase pathway in breast cancer. Breast Cancer Res 9: R32.
Bertos NR, Park M. 2011. Breast cancer—one term, many enti-
ties? J Clin Invest 121: 3789–3796.
The Cancer Genome Atlas Network. 2012. Comprehensive mo-
lecular portraits of human breast tumours.Nature 490: 61–70.
CarroMS, LimWK, AlvarezMJ, Bollo RJ, Zhao X, Snyder EY, Sul-
man EP, Anne SL, Doetsch F, ColmanH, et al. 2010. The tran-
scriptional network for mesenchymal transformation of brain
tumours. Nature 463: 318–325.
Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, Daly L,
Wels J, Theilen T, Granitto S, Zhang X, et al. 2013. The IL-
6/JAK/Stat3 feed-forward loop drives tumorigenesis and me-
tastasis. Neoplasia 15: 848–862.
Chung SS, Giehl N, Wu Y, Vadgama JV. 2014. STAT3 activation
in HER2-overexpressing breast cancer promotes epithelial–
mesenchymal transition and cancer stem cell traits. Int J
Oncol 44: 403–411.
Citri A, Yarden Y. 2006. EGF–ERBB signalling: towards the sys-
tems level. Nat Rev Mol Cell Biol 7: 505–516.
Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning
MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al. 2012.
The genomic and transcriptomic architecture of 2,000 breast
tumours reveals novel subgroups. Nature 486: 346–352.
Dalrymple SL, Becker RE, Isaacs JT. 2007. The quinoline-3-car-
boxamide anti-angiogenic agent, tasquinimod, enhances the
anti-prostate cancer efficacy of androgen ablation and taxotere
without effecting serum PSA directly in human xenografts.
Prostate 67: 790–797.
Dalrymple SL, Becker RE, Zhou H, DeWeese TL, Isaacs JT. 2012.
Tasquinimod prevents the angiogenic rebound induced by
fractionated radiation resulting in an enhanced therapeutic
response of prostate cancer xenografts. Prostate 72: 638–648.
Darnell JE. 2005. Validating Stat3 in cancer therapy. Nat Med
11: 595–596.
Debnath J, Mills KR, Collins NL, ReginatoMJ,Muthuswamy SK,
Brugge JS. 2002. The role of apoptosis in creating and main-
taining luminal spacewithin normal and oncogene-expressing
mammary acini. Cell 111: 29–40.
Debnath J,MuthuswamySK, Brugge JS. 2003.Morphogenesis and
oncogenesis of MCF-10A mammary epithelial acini grown in
three-dimensional basement membrane cultures. Methods
30: 256–268.
Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J. 2009. The
endogenous Toll-like receptor 4 agonist S100A8/S100A9 (cal-
protectin) as innate amplifier of infection, autoimmunity, and
cancer. J Leukoc Biol 86: 557–566.
Fruman DA, Rommel C. 2014. PI3K and cancer: lessons, chal-
lenges and opportunities. Nat Rev Drug Discov 13: 140–156.
Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho
CA, Cox CE, Falcone R, Fairclough R, Parsons S, et al. 2001.
Constitutive activation of Stat3 by the Src and JAK tyrosine
kinases participates in growth regulation of human breast car-
cinoma cells. Oncogene 20: 2499–2513.
GebhardtC,Nemeth J, Angel P, Hess J. 2006. S100A8 and S100A9
in inflammation and cancer. Biochem Pharmacol 72: 1622–
1631.
Grebhardt S,Muller-Decker K, Bestvater F, HershfinkelM,Mayer
D. 2014. Impact of S100A8/A9 expression on prostate cancer
progression in vitro and in vivo. J Cell Physiol 229: 661–671.
Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg
RA, Lander ES. 2009. Identification of selective inhibitors
of cancer stem cells by high-throughput screening. Cell 138:
645–659.
Hartman ZC, Yang XY, Glass O, Lei G, Osada T, Dave SS, Morse
MA,ClayTM, LyerlyHK. 2011.HER2 overexpression elicits a
proinflammatory IL-6 autocrine signaling loop that is critical
for tumorigenesis. Cancer Res 71: 4380–4391.
Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng
S, GibbWJ,WangNJ, Ziyad S, Tong F, et al. 2012. Subtype and
pathway specific responses to anticancer compounds in breast
cancer. Proc Natl Acad Sci 109: 2724–2729.
Hermani A, De Servi B, Medunjanin S, Tessier PA, Mayer D.
2006. S100A8 and S100A9 activate MAP kinase and NF-κB
signaling pathways and trigger translocation of RAGE in hu-
man prostate cancer cells. Exp Cell Res 312: 184–197.
Hibino T, Sakaguchi M, Miyamoto S, Yamamoto M, Motoyama
A, Hosoi J, Shimokata T, Ito T, Tsuboi R, Huh NH. 2013.
S100A9 is a novel ligand of EMMPRIN that promotesmelano-
ma metastasis. Cancer Res 73: 172–183.
Rodriguez-Barrueco et al.
1646 GENES & DEVELOPMENT
Hurley J, Doliny P, Reis I, Silva O, Gomez-Fernandez C, Velez P,
Pauletti G, Powell JE, Pegram MD, Slamon DJ. 2006.
Docetaxel, cisplatin, and trastuzumab as primary systemic
therapy for human epidermal growth factor receptor 2-posi-
tive locally advanced breast cancer. J Clin Oncol 24: 1831–
1838.
Hynes NE, Lane HA. 2005. ERBB receptors and cancer: the com-
plexity of targeted inhibitors. Nat Rev Cancer 5: 341–354.
Ichikawa M, Williams R, Wang L, Vogl T, Srikrishna G. 2011.
S100A8/A9 activate key genes and pathways in colon tumor
progression. Mol Cancer Res 9: 133–148.
Kallberg E, Vogl T, Liberg D, Olsson A, Bjork P, Wikstrom P,
Bergh A, Roth J, Ivars F, Leanderson T. 2012. S100A9 interac-
tion with TLR4 promotes tumor growth. PLoSOne 7: e34207.
Kaufman B, Mackey JR, ClemensMR, Bapsy PP, Vaid A, Wardley
A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, et al. 2009.
Trastuzumab plus anastrozole versus anastrozole alone for
the treatment of postmenopausal womenwith human epider-
mal growth factor receptor 2-positive, hormone receptor-pos-
itive metastatic breast cancer: results from the randomized
phase III TAnDEM study. J Clin Oncol 27: 5529–5537.
Kawai H, Minamiya Y, Takahashi N. 2011. Prognostic impact of
S100A9 overexpression in non-small cell lung cancer.Tumour
Biol 32: 641–646.
Lefebvre C, Rajbhandari P, Alvarez MJ, Bandaru P, LimWK, Sato
M, Wang K, Sumazin P, Kustagi M, Bisikirska BC, et al. 2010.
A human B-cell interactome identifies MYB and FOXM1 as
master regulators of proliferation in germinal centers. Mol
Syst Biol 6: 377.
Lemmon MA, Schlessinger J. 2010. Cell signaling by receptor
tyrosine kinases. Cell 141: 1117–1134.
Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL,
Mai E, Blattler WA, Lambert JM, Chari RV, Lutz RJ, et al.
2008. Targeting HER2-positive breast cancer with trastuzu-
mab-DM1, an antibody-cytotoxic drug conjugate. Cancer
Res 68: 9280–9290.
Luo B, Cheung HW, Subramanian A, Sharifnia T, Okamoto M,
Yang X, Hinkle G, Boehm JS, Beroukhim R, Weir BA, et al.
2008. Highly parallel identification of essential genes in can-
cer cells. Proc Natl Acad Sci 105: 20380–20385.
Marcotte R, Brown KR, Suarez F, Sayad A, Karamboulas K, Krzy-
zanowski PM, Sircoulomb F,MedranoM, Fedyshyn Y, Koh JL,
et al. 2012. Essential gene profiles in breast, pancreatic, and
ovarian cancer cells. Cancer Discov 2: 172–189.
Margolin AA, Nemenman I, Basso K, Wiggins C, Stolovitzky G,
Dalla Favera R, Califano A. 2006. ARACNe: an algorithm
for the reconstruction of gene regulatory networks in a mam-
malian cellular context. BMC Bioinformatics 7: S7.
Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J,
Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA,
MaruyamaR, et al. 2011. The JAK2/STAT3 signaling pathway
is required for growth of CD44+CD24− stem cell-like breast
cancer cells in human tumors. J Clin Invest 121: 2723–2735.
Mascarenhas J, Hoffman R. 2012. Ruxolitinib: the first FDA ap-
proved therapy for the treatment of myelofibrosis. Clin Can-
cer Res 18: 3008–3014.
Mesa RA, Yasothan U, Kirkpatrick P. 2012. Ruxolitinib.Nat Rev
Drug Discov 11: 103–104.
Moasser MM. 2007. The oncogene HER2: its signaling and trans-
forming functions and its role in human cancer pathogenesis.
Oncogene 26: 6469–6487.
Murray PJ. 2007. The JAK–STAT signaling pathway: input and
output integration. J Immunol 178: 2623–2629.
Navarro-Millan I, Singh JA, Curtis JR. 2012. Systematic review of
tocilizumab for rheumatoid arthritis: a new biologic agent tar-
geting the interleukin-6 receptor. Clin Ther 34: 788–802.
Paluch-Shimon S, Ben-BaruchN,Wolf I, Zach L, Kopolovic J, Kru-
glikova A, Modiano T, Yosepovich A, Catane R, Kaufman B.
2009. Hormone receptor expression is associated with a
unique pattern of metastatic spread and increased survival
among HER2-overexpressing breast cancer patients. Am J
Clin Oncol 32: 504–508.
Patel AM, Moreland LW. 2010. Interleukin-6 inhibition for treat-
ment of rheumatoid arthritis: a review of tocilizumab therapy.
Drug Des Devel Ther 4: 263–278.
PerouCM, Sorlie T, EisenMB, van de RijnM, Jeffrey SS, Rees CA,
Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. 2000. Mo-
lecular portraits of human breast tumours. Nature 406:
747–752.
Piovan E, Yu J, Tosello V, Herranz D, Ambesi-Impiombato A, Da
Silva AC, Sanchez-Martin M, Perez-Garcia A, Rigo I, Castillo
M, et al. 2013. Direct reversal of glucocorticoid resistance by
AKT inhibition in acute lymphoblastic leukemia. Cancer
Cell 24: 766–776.
Rawlings JS, Rosler KM, Harrison DA. 2004. The JAK/STAT sig-
naling pathway. J Cell Sci 117: 1281–1283.
Rodriguez-Barrueco R, Marshall N, Silva J. 2013. Pooled shRNA
screenings: experimental approach. Methods Mol Biol 980:
353–370.
Schlabach MR, Luo J, Solimini NL, Hu G, Xu Q, Li MZ, Zhao Z,
Smogorzewska A, Sowa ME, Ang XL, et al. 2008. Cancer pro-
liferation gene discovery through functional genomics. Sci-
ence 319: 620–624.
Schultz N, Marenstein DR, De Angelis DA, WangWQ, Nelander
S, Jacobsen A, Marks DS, Massague J, Sander C. 2011. Off-tar-
get effects dominate a large-scale RNAi screen for modulators
of the TGF-β pathway and reveal microRNA regulation of
TGFBR2. Silence 2: 3.
Silva JM, Marran K, Parker JS, Silva J, Golding M, Schlabach MR,
Elledge SJ, Hannon GJ, Chang K. 2008. Profiling essential
genes in human mammary cells by multiplex RNAi screen-
ing. Science 319: 617–620.
Sotiriou C, Pusztai L. 2009. Gene-expression signatures in breast
cancer. N Engl J Med 360: 790–800.
Soule HD, Maloney TM, Wolman SR, Peterson WD Jr, Brenz R,
McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC.
1990. Isolation and characterization of a spontaneously im-
mortalized human breast epithelial cell line, MCF-10.Cancer
Res 50: 6075–6086.
Tagliabue E, Balsari A, Campiglio M, Pupa SM. 2010. HER2 as a
target for breast cancer therapy. Expert Opin Biol Ther 10:
711–724.
Testa JR, Tsichlis PN. 2005. AKT signaling in normal and malig-
nant cells. Oncogene 24: 7391–7393.
Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J,
Nguyen M, Olsson A, Nawroth PP, Bierhaus A, et al. 2008.
RAGE, carboxylated glycans and S100A8/A9 play essential
roles in colitis-associated carcinogenesis. Carcinogenesis 29:
2035–2043.
Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo
HS, Theriault RL, Wilson J, Niland JC, Weeks JC, et al.
2012. Impact of hormone receptor status on patterns of recur-
rence and clinical outcomes among patients with human epi-
dermal growth factor-2-positive breast cancer in the National
Comprehensive Cancer Network: a prospective cohort study.
Breast Cancer Res 14: R129.
Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S,
Carpenter G, Gazdar AF, Muthuswamy SK, Arteaga CL.
Targeted therapy for HR−/HER2+ breast cancers
GENES & DEVELOPMENT 1647
2006. HER2 kinase domain mutation results in constitutive
phosphorylation and activation of HER2 and EGFR and resis-
tance to EGFR tyrosine kinase inhibitors. Cancer Cell 10:
25–38.
Weerasinghe P, Garcia GE, ZhuQ, Yuan P, Feng L,Mao L, Jing N.
2007. Inhibition of Stat3 activation and tumor growth sup-
pression of non-small cell lung cancer by G-quartet oligonu-
cleotides. Int J Oncol 31: 129–136.
Wendt MK, Balanis N, Carlin CR, Schiemann WP. 2014. STAT3
and epithelial–mesenchymal transitions in carcinomas.
JAKSTAT 3: e28975.
Wormald S, Hilton DJ. 2004. Inhibitors of cytokine signal trans-
duction. J Biol Chem 279: 821–824.
Yu J, Putcha P, Califano A, Silva JM. 2013. Pooled shRNA
screenings: computational analysis. Methods Mol Biol 980:
371–384.
Rodriguez-Barrueco et al.
1648 GENES & DEVELOPMENT
